Publication

Maisel SA, Broka D, Atwell B, Bunch T, Kupp R, Singh SK, Mehta S, Schroeder J. 2019. Stapled EGFR peptide reduces inflammatory breast cancer and inhibits additional HER-driven models of cancer. J Transl Med. 17:201. doi:10.1186/s12967-019-1939-7.

Robbins JR, Schmid RK, Hammad AY, Gamblin TC, Erickson BA. 2019 Jan. Stereotactic body radiation therapy for hepatocellular carcinoma: Practice patterns, dose selection and factors impacting survival. Cancer Med. doi:10.1002/cam4.1948.

Maggert KA. 2019. Stress: An evolutionary mutagen. Proc Natl Acad Sci U S A. 116:17616–17618. doi:10.1073/pnas.1912725116.

Baker FL, Bigley AB, Agha NH, Pedlar CR, O’Connor DP, Bond RA, Bollard CM, Katsanis E, Simpson RJ. 2019. Systemic β-Adrenergic Receptor Activation Augments the Expansion and Anti-Tumor Activity of Vγ9Vδ2 T-Cells. Front Immunol. 10:3082. doi:10.3389/fimmu.2019.03082.

Famoso J, Lemole G, Sundararajan S, Stea B. 2019. Targeting PD-L1 After Adjuvant Radiation in Subtotally Resected Primary Pineal Melanoma: A Case Report and Literature Review. J Natl Compr Canc Netw. 17:1148–1153. doi:10.6004/jnccn.2019.7336.

Beaudry JL, Kaur KD, Varin EM, Baggio LL, Cao X, Mulvihill EE, Stern JH, Campbell JE, Scherer PE, Drucker DJ. 2019. The brown adipose tissue glucagon receptor is functional but not essential for control of energy homeostasis in mice. Mol Metab. 22:37–48. doi:10.1016/j.molmet.2019.01.011.

Aryanpur PP, Renner DM, Rodela E, Mittelmeier TM, Byrd A, Bolger TA. 2019. The DEAD-box RNA helicase Ded1 has a role in the translational response to TORC1 inhibition. Mol Biol Cell. 30:2171–2184. doi:10.1091/mbc.E18-11-0702.

Smith TT, Donny EC, Luo X, Allen AM, Carroll DM, Denlinger-Apte RL, Dermody SS, Koopmeiners JS, McClernon FJ, Pacek LR, et al. 2019. The Impact of Gradual and Immediate Nicotine Reduction on Subjective Cigarette Ratings. Nicotine Tob Res. 21:S73-S80. doi:10.1093/ntr/ntz158.

Bughio F, Maggert KA. 2019. The peculiar genetics of the ribosomal DNA blurs the boundaries of transgenerational epigenetic inheritance. Chromosome Res. 27:19–30. doi:10.1007/s10577-018-9591-2.

Ji J, Tang X, Hu W, Maggert KA, Rong YS. 2019. The processivity factor Pol32 mediates nuclear localization of DNA polymerase delta and prevents chromosomal fragile site formation in Drosophila development. PLoS Genet. 15:e1008169. doi:10.1371/journal.pgen.1008169.

Danilov SM, Metzger R, Klieser E, Sotlar K, Trakht IN, Garcia JGN. 2019. Tissue ACE phenotyping in lung cancer. PLoS One. 14:e0226553. doi:10.1371/journal.pone.0226553.

Price SN, Studts JL, Hamann HA. 2019. Tobacco Use Assessment and Treatment in Cancer Patients: A Scoping Review of Oncology Care Clinician Adherence to Clinical Practice Guidelines in the U.S. Oncologist. 24:229–238. doi:10.1634/theoncologist.2018-0246.

Kovalchuk N, Zhang Q-Y, Kelty J, Van Winkle L, Ding X. 2019. Toxicokinetic Interaction between Hepatic Disposition and Pulmonary Bioactivation of Inhaled Naphthalene Studied Using -Null and CYP2A13/2F1-Humanized Mice with Deficient Hepatic Cytochrome P450 Activity. Drug Metab Dispos. 47:1469–1478. doi:10.1124/dmd.119.088930.

Gartrell RD, Marks DK, Rizk EM, Bogardus M, Gérard CL, Barker LW, Fu Y, Esancy CL, Li G, Ji J, et al. 2019. Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma. Clin Cancer Res. 25:2494–2502. doi:10.1158/1078-0432.CCR-18-2847.

Kannaiyan R, Mahadevan D. 2018. A comprehensive review of protein kinase inhibitors for cancer therapy. Expert Rev Anticancer Ther. 18:1249–1270. doi:10.1080/14737140.2018.1527688.

Teknos TN, Grecula J, Agrawal A, Old MO, Ozer E, Carrau R, Kang S, Rocco J, Blakaj D, Diavolitsis V, et al. 2018 Dec. A phase 1 trial of Vorinostat in combination with concurrent chemoradiation therapy in the treatment of advanced staged head and neck squamous cell carcinoma. Invest New Drugs. doi:10.1007/s10637-018-0696-4.

Loescher LJ, Howerter AL, Heslin KM, Azzolina CM, Muramoto ML. 2018. A Survey of Licensed Massage Therapists’ Perceptions of Skin Cancer Prevention and Detection Activities. Int J Ther Massage Bodywork. 11:4–10.

Mandava S, Keerthivasan MB, Li Z, Martin DR, Altbach MI, Bilgin A. 2018. Accelerated MR parameter mapping with a union of local subspaces constraint. Magn Reson Med. 80:2744–2758. doi:10.1002/mrm.27344.

Shelar S, Shim E-H, Brinkley GJ, Kundu A, Carobbio F, Poston T, Tan J, Parekh V, Benson D, Crossman DK, et al. 2018. Biochemical and Epigenetic Insights into L-2-Hydroxyglutarate, a Potential Therapeutic Target in Renal Cancer. Clinical Cancer Research. 24(24):6433–6446.

Keener JE, Zambrano DE, Zhang G, Zak CK, Reid DJ, Deodhar BS, Pemberton JE, Prell JS, Marty MT. 2018 Dec. Chemical additives enable native mass spectrometry measurement of membrane protein oligomeric state within intact nanodiscs. J Am Chem Soc. doi:10.1021/jacs.8b11529.

Madan N, Abdelrazek H, Patil PD, Ross MD, Roy SB, Thawani N, Hahn MF, Bremner RM, Panchabhai TS. 2018. Development of Squamous Cell Carcinoma After Pulmonary Aspergillosis in the Native Lung of a Lung Transplant Recipient: A Case Report. Transplant Proc. 50:4080–4084. doi:10.1016/j.transproceed.2018.07.034.

Chakrabarti J, Holokai L, Syu L, Steele NG, Chang J, Wang J, Ahmed S, Dlugosz A, Zavros Y. 2018. Hedgehog signaling induces PD-L1 expression and tumor cell proliferation in gastric cancer. Oncotarget. 9:37439–37457. doi:10.18632/oncotarget.26473.

Xicola RM, Manojlovic Z, Augustus GJ, Kupfer SS, Emmadi R, Alagiozian-Angelova V, Triche T, Salhia B, Carpten J, Llor X, et al. 2018. Lack of APC somatic mutation is associated with early-onset colorectal cancer in African Americans. Carcinogenesis. 39:1331–1341. doi:10.1093/carcin/bgy122.

Song JH, Singh N, Luevano LA, Padi SKR, Okumura K, Olive V, Black SM, Warfel NA, Goodrich DW, Kraft AS. 2018. Mechanisms Behind Resistance to PI3K Inhibitor Treatment Induced by the PIM Kinase. Mol Cancer Ther. 17:2710–2721. doi:10.1158/1535-7163.MCT-18-0374.

Kelly KR, Friedberg JW, Park SI, McDonagh K, Hayslip J, Persky D, Ruan J, Puvvada S, Rosen P, Iyer SP, et al. 2018. Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma. Clin Cancer Res. 24:6150–6159. doi:10.1158/1078-0432.CCR-18-0286.